FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia
The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the ...
Sanofi: Qfitlia Approval A Bright Spot As Landscape Darkens For European Pharma
Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
GlobalData on MSN4d
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients
Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
Fierce Pharma6d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...
PharmiWeb4d
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
Explore more
PharmExec4d
FDA Approves Sanofi’s Qfitlia for Prophylaxis in Patients with Hemophilia A or B
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...
PMLive4d
Sanofi’s Qfitlia granted FDA approval to treat haemophilia A or B
Sanofi’s Qfitlia (fitusiran) has been approved by the US Food and Drug Administration (FDA) as the first therapy to treat ...
FDA Approves Sanofi's Hemophilia Drug
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
Medical Dialogues6d
USFDA approves Sanofi Qfitlia for hemophilia A or B with or without inhibitors
Paris: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia ...
MPR3d
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
The Pharma Letter4d
Qfitlia scores a first with FDA approval
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for ...